
ACOG Stock Forecast & Price Target
ACOG Analyst Ratings
Bulls say
Alpha Cognition is poised for success, as shown by their promising drug ZUNVEYL's positive differentiations and potential for increased market penetration, as well as the recent settlement to eliminate future obligations and strengthen the company's cash position. Utilizing a DCF-based valuation, Alpha Cognition's prospects suggest a total enterprise value of $500M, with a 12-month price objective of $18 per share, while potential risks include sales traction and competition challenges.
Bears say
Alpha Cognition is currently overvalued with a DCF-based valuation methodology calculating its worth at $520M, which is significantly lower than its current market capitalization. Additionally, risks include the company's dependence on its one product, ZUNVEYL, to drive revenue and potential delays in achieving sales traction for the drug. Despite a recent beat on financial results, the company is still operating at a loss and has a limited cash reserve, which may lead to dilution risk in the long-term.
This aggregate rating is based on analysts' research of Alpha Cognition Inc and is not a guaranteed prediction by Public.com or investment advice.
ACOG Analyst Forecast & Price Prediction
Start investing in ACOG
Order type
Buy in
Order amount
Est. shares
0 shares